De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary ...

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

We know from TWILIGHT that ticagrelor monotherapy after an initial 3 months of DAPT also seems to be an acceptable strategy. However, in the THEMIS-PCI trial comparing aspirin/ticagrelor with ...

“Our findings suggest that de-escalating DAPT to ticagrelor monotherapy will reduce aspirin-associated major bleeding while preserving the anti-ischemic benefits of antiplatelet therapy for ...

The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...

BMI Shapes DAPT De-escalation After Primary PCI De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary percutaneous coronary ...

The filing was based on results from the phase 3 THALES trial, which showed aspirin plus Brilinta 90 mg used twice daily for 30 days resulted in a statistically significant and clinically ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...